Congratulations! You now have unlimited access to all articles from The Medicine Maker.
Complete your profile at your earliest convenience to unlock the rest of your benefits:
relevant and personalised updates about your field
access to White Papers/product profiles
digital magazine subscription
The Medicine Maker
“Welcome to the October issue. Upfront investigates how to make biopharma medicines on demand, GDUFA II, and the EMA’s fight for transparency. In our cover feature, find out what poker can teach us about the biosimilars business. NextGen looks at how to make cell therapies more widely available, and in Business, Alain J. Gilbert argues that orphan medicines are better off alone. We also sit down with Carol Lynch, Global Head Biopharmaceuticals at Sandoz.